Additional Proxy Soliciting Materials (definitive) (defa14a)
May 12 2016 - 6:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 11, 2016
MEDIVATION, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-32836
|
|
13-3863260
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
525 Market Street, 36
th
Floor
San Francisco, California 94105
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (415) 543-3470
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
x
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events.
On May 11, 2016, David Hung, M.D., Founder, President and Chief Executive Officer of Medivation, Inc. (the Company), and Jennifer Jarrett,
Chief Financial Officer of the Company, participated in a presentation at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas, NV (the BAML Healthcare Conference). A copy of the transcript from the presentation is
attached hereto at Exhibit 99.1.
Forward-Looking Statements
The attached Exhibit 99.1 contains forward-looking statements. All statements relating to events or results that may occur in the future, including but not
limited to statements regarding our future results of operations and financial position, estimated future sales of XTANDI
®
, market opportunity for our products and product candidates,
potential regulatory approvals or events, and clinical trial events or progress, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Words such as believe, opportunity, potential,
expected, potentially, may, goals, and similar expressions are intended to identify these forward-looking statements. These statements involve known and unknown risks, uncertainties and other important
factors, including risks inherent in obtaining regulatory approvals, that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Because forward-looking
statements are inherently subject to risks and uncertainties, you should not rely on these forward -looking statements as predictions of future events. For a further description of the risks and uncertainties that could cause actual results to
differ from those expressed in forward-looking statements, including risks relating to relating to our business in general, see our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 5, 2016,
under the caption Risk Factors. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed
circumstances or otherwise.
Additional Information
This Item 8.01 and attached Exhibit 99.1 are neither an offer to buy nor a solicitation of an offer to sell any securities of Medivation. No tender offer
for the shares of Medivation has commenced at this time. In connection with its proposed transaction, Sanofi may file tender offer documents, consent solicitation documents or other documents with the U.S. Securities and Exchange Commission
(SEC). If a tender offer and/or consent solicitation is commenced, Medivation will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to such tender offer and may file a solicitation of
revocation in connection with such consent solicitation. Once filed, stockholders will be able to obtain, as applicable, the tender offer statement on Schedule TO, the offer to purchase, the Solicitation/Recommendation Statement of Medivation
on Schedule 14D-9, any consent solicitation, any solicitation of revocation and related materials with respect to any tender offer or consent solicitation, free of charge, at the website of the SEC at
www.sec.gov
, and from any
information agent and/or dealer manager named in the tender offer materials. Stockholders may also obtain, at no charge, any such documents filed with or furnished to the SEC by Medivation under the SEC Filings tab in the Investor
Relations section of Medivations website at
www.medivation.com
. Stockholders are advised to read these documents, if and when they become available, including any amendments thereto, as well as any other documents relating to
any tender offer and/or consent solicitation that are filed with the SEC, carefully and in their entirety prior to making any decisions with respect to whether to tender shares or submit consents because the documents will contain important
information.
Certain Information Regarding Participants
Medivation, its directors and certain of its executive officers may be deemed to be participants in the solicitation of revocations in connection with any
Sanofi solicitation. Information regarding the names of Medivations directors and executive officers and their respective interests in Medivation by security holdings or otherwise is set forth in Medivations proxy statement for the
2016 Annual Meeting of Shareholders, as amended, filed with the SEC on April 29, 2016. Additional information can also be found in Medivations Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC
on February 26, 2016 and in Medivations latest Quarterly Report on Form 10-Q.
Non-GAAP Financial Measures
The attached Exhibit 99.1 includes non-GAAP financial measures. A reconciliation between certain historical non-GAAP financial measures and corresponding GAAP
financial measures is available on Medivations website at
www.medivation.com
within the investor relations section. Management believes this non-GAAP financial information is useful for management and investors, when considered in
conjunction with Medivations GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP financial information is not prepared under a comprehensive set
of accounting rules and should only be used to supplement an understanding of Medivations operating results as reported under U.S. GAAP.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits.
99.1
|
Transcript from the Company presentation at the BAML Healthcare Conference on May 11, 2016
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MEDIVATION, INC.
|
|
|
|
|
Dated: May 11, 2016
|
|
|
|
By:
|
|
/s/ Carolyn Tang
|
|
|
|
|
|
|
Carolyn Tang
Director, Securities and
Transactions
|
EXHIBIT INDEX
99.1
|
Transcript from the Company presentation at the BAML Healthcare Conference on May 11, 2016
|
Medivation, Inc. (MM) (NASDAQ:MDVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medivation, Inc. (MM) (NASDAQ:MDVN)
Historical Stock Chart
From Apr 2023 to Apr 2024